GlaxoSmithKline PLC (GSK): Price and Financial Metrics

GlaxoSmithKline PLC (GSK): $43.75

0.22 (+0.51%)

POWR Rating

Component Grades














  • Value is the dimension where GSK ranks best; there it ranks ahead of 94.21% of US stocks.
  • The strongest trend for GSK is in Growth, which has been heading down over the past 179 days.
  • GSK ranks lowest in Momentum; there it ranks in the 8th percentile.

GSK Stock Summary

  • Glaxosmithkline Plc's market capitalization of $116,601,940,952 is ahead of 97.83% of US-listed equities.
  • Glaxosmithkline Plc's stock had its IPO on July 9, 1986, making it an older stock than 92.35% of US equities in our set.
  • In terms of volatility of its share price, GSK is more volatile than only 10.16% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Glaxosmithkline Plc, a group of peers worth examining would be SNY, DE, IBM, CAT, and AMGN.
  • Visit GSK's SEC page to see the company's official filings. To visit the company's web site, go to

GSK Stock Price Chart Interactive Chart >

Price chart for GSK

GSK Price/Volume Stats

Current price $43.75 52-week high $46.97
Prev. close $43.53 52-week low $37.80
Day low $42.91 Volume 3,086,700
Day high $43.77 Avg. volume 5,345,907
50-day MA $43.74 Dividend yield 3.13%
200-day MA $42.83 Market Cap 111.20B

GlaxoSmithKline PLC (GSK) Company Bio

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company’s wellness products include Panadol and Panadol Cold & Flu, ENO and Tums - antacids, and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate - treatment of nicotine withdrawal, Sensodyne - to ttreat and prevent dental sensitivity, Polident, Poligrip, and Corega to enhance comfort of fitted denture, and Aquafresh for the prevention of gum disease and bad breath. The company was founded in 1935 and is based, the United Kingdom.

GSK Latest News Stream

Event/Time News Detail
Loading, please wait...

GSK Latest Social Stream

Loading social stream, please wait...

View Full GSK Social Stream

Latest GSK News From Around the Web

Below are the latest news stories about Glaxosmithkline Plc that investors may wish to consider to help them evaluate GSK as an investment opportunity.

GlaxoSmithKline: Set to Make Investors Very Happy

After listening to Emma Walmsley, the CEO of GlaxoSmithKline (GSK), at the J.P. Morgan Healthcare Conference on January 11, 2022, I am confident that she and her management team have a plan to drive shareholder value for years to come.  First and foremost, what I like most about Walmsley’s time as CEO is that she has replaced over 85% of the top 125 leaders at GSK. She has also brought in outside perspectives by replacing over 30% of those top 125 leaders with people from outside the organization. Walmsley has also stated that she intends to split the company into two by the middle of this year.

Tim O'Rourke on TipRanks | February 25, 2022

VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment

VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.

Yahoo | February 25, 2022

CDC expected to loosen COVID face-mask advice on Friday, and Canada authorizes first plant-based vaccine

The Centers for Disease Control and Prevention is expected to announce later Friday a loosening of federal face-mask requirements that will mean that most Americans will no longer be advised to wear them in indoor spaces.

Yahoo | February 25, 2022

Allscripts' (MDRX) Q4 Earnings Beat Estimates, Margins Up

Allscripts' (MDRX) robust Q4 results demonstrate strength in both segments.

Yahoo | February 25, 2022

Pharma Stock Roundup: GSK, SNY Face Pipeline Setbacks, AZN Cancer Study Meets Goals

Glaxo (GSK) and Sanofi (SNY) announce pipeline setbacks. AstraZeneca's (AZN) HER2-low metastatic breast cancer study on Enhertu succeeds.

Yahoo | February 25, 2022

Read More 'GSK' Stories Here

GSK Price Returns

1-mo 2.41%
3-mo 0.79%
6-mo 2.70%
1-year 13.36%
3-year 22.74%
5-year 31.91%
YTD 1.39%
2021 26.64%
2020 -17.79%
2019 29.12%
2018 13.70%
2017 -3.03%

GSK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GSK Dividend History

Continue Researching GSK

Here are a few links from around the web to help you further your research on Glaxosmithkline Plc's stock as an investment opportunity:

Glaxosmithkline Plc (GSK) Stock Price | Nasdaq
Glaxosmithkline Plc (GSK) Stock Quote, History and News - Yahoo Finance
Glaxosmithkline Plc (GSK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8894 seconds.